Check to see if your insurance is accepted by this provider.
Please contact your insurance provider to confirm if your health plan is accepted.
Dr. Marsland has over 30 years of experience in treating patients with hematologic and oncologic issues. He believes the doctor-patient relationship is a team with both parties involved in determining the best plan of care. He actively supports the St. Joseph Clinical Research Program. Dr. Marsland recently moved from Florida to Northern California (April 2017) with his wife to be near his family of three daughters and his new grandson. His hobbies include fine dining and good wine. The Sonoma/Napa County area are a great fit.
I. Biomarker Analyses From a Randomized, Placebo-Controlled, Phase Illb Trial Comparing Bevacizumab With or Without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer, May' 13. Submission to Journal of Clinical Oncology.
2. Atlas: Randomized, Double-Blind, Placebo-Controlled, Phase ll!B Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, 2012. Johnson, B., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kresse!, B., Lin, Chin-Yu., Marsland, T., Patel, T., Polikoff, J., Rubin, M., White, L., Chin-Hsin Yang, J., Bowden, C., Miller, V. Journal of Clinical Oncology 2012.
3. Marsland, Lung Cancer Screening: A New Era Oncology, February 2012.
4. Marsland, Reducing Cancer Costs & Improving Quality through Collaboration with payers, Journal of Oncology Practice, Sept. 2010.
5. S.L. Wong, P. Mamgu, T. Chati, G. Dodd, G. Dorfman, C. Emg, T. Marsland. et al. American Society of Clinical Oncology, 2009 Clinical Epredesine Review of RFA of Hepatic met Journal of Clinical Oncology. 28:493-508, 2010.
6. B. McAnemy, T. Marsland, K. King; News and Notes from 2009 CAC. Meeting Medical Necessity, off label News and Notes From the 2009 Carrier Advisory Committee Meeting: Medical Necessity, Off-Label Chemotherapy, and More, Journal of Oncology Practices; 301-304, Nov. 09.
7, Matuzumab in second line treatment for patients with Stage III & IV NSCLC, J. Thorac One. '09.
8. J.A. Bubis, I.A. Marsland, K.M, Justice, D. Edwards. Features of patients (pts) with metastatic breast cancer
(MBC) and a circulating tumor cell count (CTCC) of 0. Accepted for poster discussions, San Antonio Breast Cancer Symposium, 2007. Abstract l 06.
9. C.P. Belani, S. Ramalingam, M. Schreede, R. Steis, R. Guidice, T. Marsland, B. Butler. Phase II study of Cetuximab in combination with Carboplatin and Docetaxel for patients with advanced/Metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:764.
10. Gray, J., Spigel, D., Hainsworth, J., Vazquez, E., Peyton, J., Raefsky, E., Malik, R., Marsland, T., Waples, J., Greco, F. Maintenance gefitnib (0) after chemo radiotherapy (CRT) in patients (pts) with unresectable stage IIIA/B non-small cell lung cancer (NSCLC): A Phase II trial of Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, Vol. 24, No. 18S (June Supplement), 2006: 7188.
11. Shipley, D., Hainsworth, J., Spigel, D., Gray, J., Barton, J., Switzer, A., Nicolau, M,, Marsland, T., Jospeh, G., Greco, F., Topotecan: Weekly Intravenous (IV) Schedule Similar to Standard 5-Day IV.Schedule as Second-Line Therapy for Relapsed Small Cell Lung Cancer (SCLC) -A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), 2006: 7083.
12. Result ofa Phase II trial ofGencitabine in Patients with Non-Small Cell Lung Cancer and Performance Status of Two. Clinical Lung Cancer Trials, Volume 6 #4, 2005.
13. I.A, Marsland, D.H. Garfield, M.M. Khan, R.M. Look, K.A. Boehm, L.A. Smar. Sequential vs Concurrent Paclitaxel and Carboplatin for treatment of advanced non-small cell lung cancer (ANSCLC) in elderly patients with poor performance status: results of two Phase II, multicenter trials. US Oncology Research Inc., 2004.
14. Neubauer, M., Reynolds, C., Joppert, M., Whittaker, T,, Ahmad, Y., Ghaddar, H., Marsland, T., Asmar, L., US Oncology Research, Inc,, Houston, TX. Preliminary results of a phase II trial utilizing Gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceeding (Post Meeting Edition). Volume 22, No I 4S (July Supplement), 2004: 1721.
I5. Sequential Verses Concurrent Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small Cell Lung Cancer in Elderly and Patients with Poor Performance Status. Result of our Phase II Trial Lung Cancer, June, 2004.
16. Phase II Trial Utilizing Oemcitabine in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status 2, American Society of Clinical Oncology Abstracts, 2004, #7121 Poster Presentation.
17. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non- Hodgkin's, Vol. 3 #4, 2003.
18. Phase II Study of First-line Chemotherapy Using CT-2103 in Patients with NSCLC who are Less than or Equal to 70 years of Age or who have PS= 2. Abstract, 2002.
19. Joppert, M., Garfield, D., Gregurich, M., Nemunaitis, J,, Marsland, T., Khandelwal, P., Asmar, L. US Oncology, Houston, TX. First-line Chemotherapy with Topotecan and Gemcitabine for Patients with Advanced Non-Small Cell Lung Cancer. American Society of Clinical Oncology Abstracts, 2002, #2671.
20. Phase II Study if Sequential Chemo-Therapy followed by Maintenance Therapy with Oral Orzel in Patients with Stage IIIB & IV Non-Small Cell Lung Cancer. Abstract
2I. U.S. Oncology Clinical Research the Role and Function of the Lung Committee. Abstract Second. World Conference on Clinical Research for Lung Cancer, 2002.
22. Garbo, L., Marsland, T., Garfield, D., Khan, M., Asmar, L. US Oncology, Houston, TX., A phase II Study of Weekly Paclitaxel (Taxol®) In Stage IIIB, IV, or Relapsed After Local Therapy, Non-Small Cell Lung Cancer
(NSCLC) Patients with a Performance Status of2 and/ or 70 Years of Age, with (Paraplatin®) Administered at Disease Progression. ASCO, 2001. Abstract #2821.
23. Phase II Study of Weekly Taxol and Paraplatin in Stage IIIB & IV NSCLC in patients who are Less Than Equal to Age 70 and a Male with PS II. ASCO Abstract, 2001. #2819.
24. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non-Hodgkin's. American Society Hematology Abstract, 2000.
25. Estrogen Receptor Status and Response to Advance Breast Cancer. CANCER, 46;2919-2921, 1980.
26. Estrogen Receptor Status and Response Chemotherapy. ASCO Abstracts, 1979.
ASCO Self Evaluation Program
Veridex: Role of Circulation Tumor Cells
Cost of Healthcare with ION
Healthcare Economics (Con/era Group)
2012 Stress of Community Oncology Practices
2012 Value Based Cancer Care Conferences
2013 Value Based Cancer Care Conferences
Doctor of Medicine
Bachelor of Arts
NIH Office of Human Subjects Research Course on the Protection of Human Research Subjects
At Providence, we're dedicated to providing you quality, personalized health care. We are constantly striving to optimize your experience.
As part of ensuring you have a positive experience with Providence, our online provider directory includes ratings and patient comments for select providers. More about our survey.
I feel comfort table and good
Excellent service. Always received a reminder/call to schedule follow-up appointment. No issues/complaints.
Service has always been great.
Always receive great care from Dr. Thomas Marsland.
Listened to current health problems
I forget to bring things up because it always seems like there's not enough time and I'm not really asked about new symptoms.
Always seems interested in my personal well being overall, including the specific diagnosis for which I am seeing my care provider.
Less than 7 minute telemedicine visit including sign in time for md. He was also late
Doctor Marsland was very professional and read my chart and knew what to ask and very respectful. And explain to me what test he wanted done to get me back healthy.
Dr. Marsland is a referral consultant from my primary care. All of my contacts with him have been excellent.
Everyone is very professional and kind
best of care for my situation
Very positive experience.
For the last 3 1/2 years that I have had excellent care from Dr. Thomas Marsland, my oncologist.
the visit went exactly as I expected and was quick and efficient
very caring team. Thank you
my experience over the last two years has been completely exemplary. I'm so grateful to have been referred to this provider.
It was a very good experience.
Dr. Marsland and staff were extremely prompt in getting ultrasound results to me.
always kindly and gave good information
routine follow up visit. nothing much to say. dr marsland is great and always listens to everything and i dont feel rushed. Also the girls in the front were great. Finally the rude and inefficient ones seem to be gone. They both had smiles and were very pleasant. Got all my scheduling questions answered and on my way. it is a big change from who used to be the ones who greeting you and did scheduling.
Provider very attentive to complete health, including emotional. Very supportive.
Good: Dr. Marsland listened well, and presented as an expert and very capable physician with good skills in maintaining a relaxed but productive interaction. I liked his approach very much. Not So Good: The interview Zoom credentials provided by the office were incorrect, the session was rushed as a result, and - after receiving information concerning a serious disorder - I received no response to written questions seeking clarification.
Efficient, Professional, and Humanitarian.
I have always received very helpful and courteous and caring interaction between everyone in that office thru the years.
Everyone in the office behaved in a very courteous and thoughtful manner. I believe there is a need to have the pre-visit forms edited for duplication of questions.